| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H18ClFN4O2 |
| Molecular Weight | 448.877 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC(COC2=CC=C(NC3=C4C=C(NC(=O)C=C)C=CC4=NC=N3)C=C2Cl)=CC=C1
InChI
InChIKey=MVZGYPSXNDCANY-UHFFFAOYSA-N
InChI=1S/C24H18ClFN4O2/c1-2-23(31)29-17-6-8-21-19(11-17)24(28-14-27-21)30-18-7-9-22(20(25)12-18)32-13-15-4-3-5-16(26)10-15/h2-12,14H,1,13H2,(H,29,31)(H,27,28,30)
| Molecular Formula | C24H18ClFN4O2 |
| Molecular Weight | 448.877 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
AST-1306, also known as Allitinib, is an orally active potent, selective, irreversible inhibitor of the HER family of receptor tyrosine kinases. AST-1306 inhibits the enzymatic activities of wild-type epidermal growth factor receptor (EGFR) and ErbB2 as well as EGFR resistant mutant in both cell-free and cell-based systems. AST1306 potently suppressed tumor growth in ErbB2-overexpressing adenocarcinoma xenograft and FVB-2/N(neu) transgenic breast cancer mouse models. Allitinib is in Phase I clinical trial for the treatment of advanced solid tumors. Serious adverse effects detected were: diarrhea, dehydration and hyperbilirubinemia.
Originator
Approval Year
PubMed
Showing 1 to 5 of 6 entries
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Tmax | PHARMACOKINETIC |
3.56 hours [0.91 to 6.21] (average) |
AT DAY 1 |
|
||
| Biological Half-life | PHARMACOKINETIC |
6.61 hours [4.85 to 8.37] (average) |
IN CANCER PATIENTS |
|
||
| Biological Half-life | PHARMACOKINETIC |
6.3 hours [3.22 to 9.38] (average) |
THREE TIMES A DAY |
|
||
| Tmax | PHARMACOKINETIC |
2.83 hours [0.68 to 4.98] (average) |
IN CANCER PATIENTS |
|
||